Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies
This article reviews recent progress in the mechanisms of action of HDAC6 inhibitors for the treatment of B cell-associated hematological malignancies, such as multiple myeloma and B cell non-Hodgkin lymphoma, which are often resistant to targeted therapies.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Drugs & Pharmacology | Hematology | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma